Payment overview · 2025
General Payments
$1,345.45
71 reported records · 16 companies
Healthcare provider profile · identity verified
Suah Park
Physician Assistants & Advanced Practice Nursing Providers|Nurse Practitioner|Family · LAKEWOOD, WA · NPI 1316563091
Verified facts
What the public records show
CMS Open Payments records show Suah Park received $1,345.45 in general payments during 2025 across 71 reported records.
ABBVIE INC. accounted for 26.4% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 25 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Creon, Farxiga, Jardiance, Linzess.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported CREON as an associated drug or biological on 91561 records involving 20616 distinct recipient NPIs. Public Medicare Part D data also shows 146 claims for Creon by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LINZESS as an associated drug or biological on 87954 records involving 21815 distinct recipient NPIs. Public Medicare Part D data also shows 70 claims for Linzess by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 36 claims for Farxiga by this doctor in 2024.
Boehringer Ingelheim Pharmaceuticals, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 123636 records involving 49438 distinct recipient NPIs. Public Medicare Part D data also shows 83 claims for Jardiance by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 24 claims for Eliquis by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| ABBVIE INC. | Unresolved — no canonical attribution shown | $354.65 | 26.4% | 21 | 2025 |
| Orexo US, Inc. | Unresolved — no canonical attribution shown | $231.42 | 17.2% | 16 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $196.16 | 14.6% | 8 | 2025 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $74.29 | 5.5% | 3 | 2025 |
| Abbott Laboratories | Unresolved — no canonical attribution shown | $67.91 | 5.0% | 2 | 2025 |
| Phathom Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $63.45 | 4.7% | 3 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $59.42 | 4.4% | 3 | 2025 |
| Viatris Specialty LLC | Unresolved — no canonical attribution shown | $53.44 | 4.0% | 3 | 2025 |
| Aimmune Therapeutics, Inc. | Unresolved — no canonical attribution shown | $45.27 | 3.4% | 2 | 2025 |
| Alexion Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $42.91 | 3.2% | 2 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $41.67 | 3.1% | 2 | 2025 |
| Esperion Therapeutics, Inc. | Unresolved — no canonical attribution shown | $39.20 | 2.9% | 2 | 2025 |
| Daiichi Sankyo Inc. | Unresolved — no canonical attribution shown | $21.42 | 1.6% | 1 | 2025 |
| Eisai Inc. | Unresolved — no canonical attribution shown | $18.86 | 1.4% | 1 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $17.75 | 1.3% | 1 | 2025 |
| Agios Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $17.63 | 1.3% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $1,276.65 | 69 |
| Long term medical supply or device loan | $49.95 | 1 |
| Education | $18.85 | 1 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| CREON Normalized: creon |
Drug | ABBVIE INC. | $259.28 | 16 | 2025 |
Source payment records
|
|||||
| LINZESS Normalized: linzess |
Drug | ABBVIE INC. | $250.04 | 15 | 2025 |
Source payment records
|
|||||
| Zubsolv Normalized: zubsolv |
Drug | Orexo US, Inc. | $231.42 | 16 | 2025 |
Source payment records
|
|||||
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $128.42 | 5 | 2025 |
Source payment records
|
|||||
| QULIPTA Normalized: qulipta |
Drug | ABBVIE INC. | $95.37 | 5 | 2025 |
Source payment records
|
|||||
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $95.37 | 5 | 2025 |
Source payment records
|
|||||
| JARDIANCE Normalized: jardiance |
Drug | Boehringer Ingelheim Pharmaceuticals, Inc. | $74.29 | 3 | 2025 |
Source payment records
|
|||||
| VOQUEZNA Normalized: voquezna |
Drug | Phathom Pharmaceuticals, Inc. | $63.45 | 3 | 2025 |
Source payment records
|
|||||
| YUPELRI Normalized: yupelri |
Drug | Viatris Specialty LLC | $53.44 | 3 | 2025 |
Source payment records
|
|||||
| FREESTYLE INSULINX Normalized: freestyle insulinx |
Device | Abbott Laboratories | $49.95 | 1 | 2025 |
Source payment records
|
|||||
| BREZTRI Normalized: breztri |
Drug | AstraZeneca Pharmaceuticals LP | $48.70 | 2 | 2025 |
Source payment records
|
|||||
| ZENPEP Normalized: zenpep |
Drug | Aimmune Therapeutics, Inc. | $45.27 | 2 | 2025 |
Source payment records
|
|||||
| STRENSIQ Normalized: strensiq |
Biological | Alexion Pharmaceuticals, Inc. | $42.91 | 2 | 2025 |
Source payment records
|
|||||
| SHINGRIX Normalized: shingrix |
Biological | GlaxoSmithKline, LLC. | $40.20 | 2 | 2025 |
Source payment records
|
|||||
| NEXLETOL Normalized: nexletol |
Drug | Esperion Therapeutics, Inc. | $39.20 | 2 | 2025 |
Source payment records
|
|||||
| INJECTAFER Normalized: injectafer |
Drug | Daiichi Sankyo Inc. | $21.42 | 1 | 2025 |
Source payment records
|
|||||
| OTEZLA Normalized: otezla |
Drug | Amgen Inc. | $21.24 | 1 | 2025 |
Source payment records
|
|||||
| REPATHA Normalized: repatha |
Biological | Amgen Inc. | $21.24 | 1 | 2025 |
Source payment records
|
|||||
| EVENITY Normalized: evenity |
Biological | Amgen Inc. | $20.43 | 1 | 2025 |
Source payment records
|
|||||
| TRELEGY ELLIPTA Normalized: trelegy ellipta |
Drug | GlaxoSmithKline, LLC. | $19.22 | 1 | 2025 |
Source payment records
|
|||||
| FARXIGA Normalized: farxiga |
Drug | AstraZeneca Pharmaceuticals LP | $19.04 | 1 | 2025 |
Source payment records
|
|||||
| Leqembi Normalized: leqembi |
Drug | Eisai Inc. | $18.86 | 1 | 2025 |
Source payment records
|
|||||
| FREESTYLE LIBRE 3 Normalized: freestyle libre 3 |
Device | Abbott Laboratories | $17.96 | 1 | 2025 |
Source payment records
|
|||||
| PYRUKYND Normalized: pyrukynd |
Drug | Agios Pharmaceuticals, Inc. | $17.63 | 1 | 2025 |
Source payment records
|
|||||
| VIBERZI Normalized: viberzi |
Drug | ABBVIE INC. | $15.41 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| CREON creon |
2025 | Creon | 2024 | 146 | exact normalized | Medicare Part D |
| FARXIGA farxiga |
2025 | Farxiga | 2024 | 36 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| JARDIANCE jardiance |
2025 | Jardiance | 2024 | 83 | exact normalized | Medicare Part D |
| LINZESS linzess |
2025 | Linzess | 2024 | 70 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | CREON open payments reported associated product |
CMS Open Payments — General Payments 91561 supporting records · 20616 recipient NPIs · example record 1201352608 |
Creon · 2024 Exact normalized brand match · 1 Part D row |
146 | 33 |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LINZESS open payments reported associated product |
CMS Open Payments — General Payments 87954 supporting records · 21815 recipient NPIs · example record 1201352608 |
Linzess · 2024 Exact normalized brand match · 1 Part D row |
70 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
36 | suppressed by CMS |
| Boehringer Ingelheim Pharmaceuticals, Inc. Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 123636 supporting records · 49438 recipient NPIs · example record 1221811583 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
83 | 15 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
24 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 589 | 155 |
| Amlodipine Besylate | Amlodipine Besylate | 517 | 131 |
| Omeprazole | Omeprazole | 389 | 96 |
| Metformin Hcl | Metformin Hcl | 352 | 94 |
| Meloxicam | Meloxicam | 291 | 100 |
| Losartan Potassium | Losartan Potassium | 243 | 57 |
| Lisinopril | Lisinopril | 204 | 58 |
| Levothyroxine Sodium | Levothyroxine Sodium | 202 | 52 |
| Metoprolol Succinate | Metoprolol Succinate | 200 | 44 |
| Gabapentin | Gabapentin | 195 | 60 |
| Tamsulosin Hcl | Tamsulosin Hcl | 172 | 44 |
| Creon | Lipase/Protease/Amylase | 146 | 33 |
| Pantoprazole Sodium | Pantoprazole Sodium | 133 | 30 |
| Simvastatin | Simvastatin | 130 | 35 |
| Lidocaine | Lidocaine | 128 | 20 |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 124 | 87 |
| Tramadol Hcl | Tramadol Hcl | 122 | 25 |
| Donepezil Hcl | Donepezil Hcl | 121 | 24 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 105 | 26 |
| Pioglitazone Hcl | Pioglitazone Hcl | 101 | 30 |
| Fenofibrate | Fenofibrate | 95 | 24 |
| Diclofenac Sodium | Diclofenac Sodium | 93 | 24 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 91 | 22 |
| Ibuprofen | Ibuprofen | 90 | 21 |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 89 | 45 |
| Famotidine | Famotidine | 88 | 20 |
| Furosemide | Furosemide | 85 | 24 |
| Jardiance | Empagliflozin | 83 | 15 |
| Metoprolol Tartrate | Metoprolol Tartrate | 83 | 21 |
| Hydrochlorothiazide | Hydrochlorothiazide | 82 | 22 |
| Alendronate Sodium | Alendronate Sodium | 81 | 29 |
| Finasteride | Finasteride | 81 | 19 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 80 | 16 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 76 | 21 |
| Alprazolam | Alprazolam | 75 | 23 |
| Glimepiride | Glimepiride | 71 | 19 |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 71 | 21 |
| Zolpidem Tartrate | Zolpidem Tartrate | 71 | 13 |
| Fluticasone Propionate | Fluticasone Propionate | 70 | 27 |
| Linzess | Linaclotide | 70 | suppressed |
| Trazodone Hcl | Trazodone Hcl | 68 | 17 |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 67 | 48 |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 67 | 17 |
| Carvedilol | Carvedilol | 65 | 14 |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 65 | 12 |
| Azithromycin | Azithromycin | 61 | 53 |
| Lovastatin | Lovastatin | 58 | 15 |
| Baclofen | Baclofen | 57 | 38 |
| Olmesartan-Hydrochlorothiazide | Olmesartan/Hydrochlorothiazide | 57 | 15 |
| Clopidogrel | Clopidogrel Bisulfate | 54 | 13 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 53 | 17 |
| Hydralazine Hcl | Hydralazine Hcl | 52 | 11 |
| Atenolol | Atenolol | 50 | 17 |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 50 | suppressed |
| Clobetasol Propionate | Clobetasol Propionate | 49 | 19 |
| Escitalopram Oxalate | Escitalopram Oxalate | 49 | suppressed |
| Montelukast Sodium | Montelukast Sodium | 49 | 13 |
| Potassium Chloride | Potassium Chloride | 49 | 12 |
| Sertraline Hcl | Sertraline Hcl | 49 | 13 |
| Oxycodone Hcl | Oxycodone Hcl | 48 | 15 |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 47 | 16 |
| Pravastatin Sodium | Pravastatin Sodium | 45 | 14 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 42 | 11 |
| Metformin Hcl Er | Metformin Hcl | 40 | suppressed |
| Lorazepam | Lorazepam | 39 | suppressed |
| Alcohol Swabs | Alcohol Antiseptic Pads | 37 | 14 |
| Farxiga | Dapagliflozin Propanediol | 36 | suppressed |
| Megestrol Acetate | Megestrol Acetate | 36 | suppressed |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 35 | 29 |
| Xarelto | Rivaroxaban | 35 | suppressed |
| Ozempic | Semaglutide | 34 | suppressed |
| Sucralfate | Sucralfate | 34 | suppressed |
| Spironolactone | Spironolactone | 33 | suppressed |
| Hydrocortisone | Hydrocortisone | 31 | suppressed |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 30 | suppressed |
| Celecoxib | Celecoxib | 29 | suppressed |
| Sumatriptan Succinate | Sumatriptan Succinate | 29 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 29 | 15 |
| Estradiol | Estradiol | 28 | suppressed |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 28 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 28 | 13 |
| Naproxen | Naproxen | 28 | 13 |
| Quetiapine Fumarate | Quetiapine Fumarate | 28 | suppressed |
| Buprenorphine-Naloxone | Buprenorphine Hcl/Naloxone Hcl | 27 | suppressed |
| Olanzapine | Olanzapine | 27 | suppressed |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 27 | suppressed |
| Allopurinol | Allopurinol | 26 | suppressed |
| Januvia | Sitagliptin Phosphate | 26 | suppressed |
| Nitroglycerin | Nitroglycerin | 26 | suppressed |
| Ranolazine Er | Ranolazine | 26 | suppressed |
| Vascepa | Icosapent Ethyl | 26 | suppressed |
| Felodipine Er | Felodipine | 25 | suppressed |
| Fenofibrate | Fenofibrate Nanocrystallized | 25 | suppressed |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 25 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 25 | suppressed |
| Aripiprazole | Aripiprazole | 24 | suppressed |
| Eliquis | Apixaban | 24 | suppressed |
| Dexlansoprazole Dr | Dexlansoprazole | 23 | suppressed |
| Duloxetine Hcl | Duloxetine Hcl | 23 | suppressed |
| Dicyclomine Hcl | Dicyclomine Hcl | 22 | suppressed |
| Glipizide | Glipizide | 22 | suppressed |
| Trulicity | Dulaglutide | 22 | suppressed |
| Calcitriol | Calcitriol | 21 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 21 | suppressed |
| Janumet | Sitagliptin Phos/Metformin Hcl | 21 | suppressed |
| Alcohol Prep Pads | Alcohol Antiseptic Pads | 20 | suppressed |
| Memantine Hcl | Memantine Hcl | 20 | suppressed |
| Promethazine Hcl | Promethazine Hcl | 20 | suppressed |
| Clotrimazole | Clotrimazole | 19 | suppressed |
| Pregabalin | Pregabalin | 19 | suppressed |
| Raloxifene Hcl | Raloxifene Hcl | 19 | suppressed |
| Memantine Hcl Er | Memantine Hcl | 18 | suppressed |
| Minoxidil | Minoxidil | 17 | suppressed |
| Digoxin | Digoxin | 16 | suppressed |
| Glipizide Er | Glipizide | 16 | suppressed |
| Insulin Lispro Kwikpen U-100 | Insulin Lispro | 16 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 16 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 15 | suppressed |
| Clonazepam | Clonazepam | 15 | suppressed |
| Klor-Con M20 | Potassium Chloride | 15 | suppressed |
| Mupirocin | Mupirocin | 15 | suppressed |
| Amlodipine-Olmesartan | Amlodipine Bes/Olmesartan Med | 14 | suppressed |
| Cephalexin | Cephalexin | 14 | suppressed |
| Citalopram Hbr | Citalopram Hydrobromide | 14 | suppressed |
| Fluoxetine Hcl | Fluoxetine Hcl | 14 | suppressed |
| Mounjaro | Tirzepatide | 14 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 13 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 13 | suppressed |
| Tacrolimus | Tacrolimus | 13 | suppressed |
| Amiodarone Hcl | Amiodarone Hcl | 12 | suppressed |
| Bupropion Xl | Bupropion Hcl | 12 | suppressed |
| Dutasteride | Dutasteride | 12 | suppressed |
| Methylprednisolone | Methylprednisolone | 12 | 11 |
| Prednisone | Prednisone | 12 | suppressed |
| Solifenacin Succinate | Solifenacin Succinate | 12 | suppressed |
| Betamethasone Dipropionate | Betamethasone Dipropionate | 11 | suppressed |
| Dextroamphetamine-Amphet Er | Dextroamphetamine/Amphetamine | 11 | suppressed |
| Dextroamphetamine-Amphetamine | Dextroamphetamine/Amphetamine | 11 | suppressed |
| Metoclopramide Hcl | Metoclopramide Hcl | 11 | suppressed |
| Propranolol Hcl Er | Propranolol Hcl | 11 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $1,345.45 · 71 records | ABBVIE INC. | AIRSUPRA, BREZTRI, CREON, EVENITY, FARXIGA, FREESTYLE INSULINX, FREESTYLE LIBRE 3, INJECTAFER, JARDIANCE, LINZESS, Leqembi, NEXLETOL, OTEZLA, PYRUKYND, QULIPTA, REPATHA, SHINGRIX, STRENSIQ, TRELEGY ELLIPTA, UBRELVY, VIBERZI, VOQUEZNA, YUPELRI, ZENPEP, Zubsolv | 5 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Creon play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error